Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05631080
Other study ID # Mans 22-4-2016
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date January 2015
Est. completion date September 2024

Study information

Verified date November 2022
Source Mansoura University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We will compare oncological and functional outcomes of anatomical endoscopic enucleation of the prostate (AEEP) versus continued medical treatment in low-risk prostate cancer patients for whom an active surveillance protocol was selected.


Description:

Prostate cancer is the most common cancer in men; in 2018 1,276,106 new cases of prostate cancer were reported worldwide (1). The diagnosis of prostate cancer is based on the microscopic evaluation of prostate tissue obtained via needle biopsy. The International Society of Urological Pathology (ISUP) Consensus system assigns new Grade Groups from 1 to 5, derived from the Gleason score (2). Clinicians have stratified the diagnosis into low, intermediate, and high-risk disease based on the sum of Gleason patterns, prostate specific antigen (PSA) level, and clinical stage (3). Recently The National Comprehensive Cancer Network risk stratification uses a 5-tier system by adding very low- and very high- as a subdivision of the low- and high-risk groups (4). Men diagnosed with localized disease (defined as no regional lymph nodes or distant metastases) have 3 primary options: expectant management, surgery and radiation. Expectant management (monitoring for prostate cancer progression while not undergoing definitive therapy) consists of watchful waiting and active surveillance (5). According to The Prostate Testing for Cancer and Treatment (ProtecT) trial which randomized 1643 localized prostate cancer men to active monitoring, surgery, or radiation. At 120 months, ProtecT found that 1.5% of patients on active monitoring died from prostate cancer, which did not differ significantly from the 0.9% after surgery or the 0.7% after radiation (6). The use of active surveillance (AS) for men with low-risk prostate cancer (PCa) is well established, although the criteria for admission to a protocol vary according to the institution. (7-9) Men with significantly enlarged prostates (>100 g) may be assigned a high-risk category when their prostate-specific antigen (PSA) rises above 10 ng/ml, although there is evidence AS is safe in this population. (10) In the presence of lower urinary tract symptoms (LUTS), men with significantly enlarged prostates often undergo radical prostatectomy (RP) to treat PCa and coexisting LUTS. This approach, which prioritizes oncologic control, may increase surgical morbidity for patients who otherwise might continue AS after an outlet procedure to address their LUTS. The use of holmium laser enucleation of the prostate (HoLEP) for the management of LUTS in men with significantly enlarged prostates and coexisting low-risk PCa has not been prospectively studied. HoLEP has proven to be a safe and effective treatment for men with LUTS. (11) Incidental detection of malignancy at the time of HoLEP ranges from 5% to 13% in men without a prior diagnosis of PCa, and there is evidence PSA has improved sensitivity for cancer progression in the post-HoLEP setting. (12-15) The management of T1a-b PCa incidentally discovered after transurethral resection of prostate (TURP) has been well documented with AS recommended for most patients. (16-18) However, the management of men with known low-risk PCa, clinically significant LUTS, and significantly enlarged prostates remains underexplored. Herein, we prospectively assess patients with low-risk PCa on AS who underwent AEEP for clinically significant LUTS and enlarged prostate gland size. Our study focuses on functional and oncologic outcomes.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date September 2024
Est. primary completion date September 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Life expectancy >/= 10 years 2. Low risk prostate cancer with minor institutional amendment of EAU guidelines: - PSA < 10 ng/ml or up to 20 ng/ml if PSA density is more than 15% - Stage T1, T2a. - Gleason score <7 (ISUP grade 1) 3. Bladder outlet obstruction: - IPSS > 9 - Peak flow rate (Qmax < 15) - Imperative indication for BOO surgery Exclusion criteria: - Patients who are not willing - Patients with bladder dysfunction (cystopathy) or other infravesical cause of obstruction other than prostate

Study Design


Intervention

Procedure:
Anatomical Endoscpic enucleation of the Prostate
Transurethral endoscopic enucleation of the prostate adenoma

Locations

Country Name City State
Egypt Urology and nephrology center Mansoura DK

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary PSA progression changes of PSA level from baseline to one year follow up following active treatment one year
Primary radiological progression cancer progression as depicted by multiparametric MRI one year
Secondary relief of bladder outlet obstruction improvement of urine flow parameters as depicted by peak flow rate (ml/sec) one year
Secondary relief of lower urinary tract symptoms improvement of urinary symptoms as depicted by symptom score (International prostate symptom score) one year
Secondary 2 years progression free survival PSA, Radiological and grade progression whenever biopsy is indicated 2 years
Secondary 5 years progression free survival PSA, Radiological and grade progression whenever biopsy is indicated 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT03457805 - Prostatic Artery Embolization in Advanced Prostate Cancer N/A
Completed NCT00507455 - Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction Phase 2
Recruiting NCT04626167 - Concomitant Renal and Urinary Bladder Allograft Transplantation Early Phase 1
Not yet recruiting NCT06422312 - A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients. N/A
Suspended NCT01779349 - Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter" N/A
Not yet recruiting NCT01388348 - Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study N/A
Completed NCT00710749 - The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects N/A
Recruiting NCT03486639 - Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity
Enrolling by invitation NCT02869061 - Effectiveness and Safety of Adipose-derived Regenerative Cells for Reduction of Risk of Bladder Neck Contracture Phase 1/Phase 2
Completed NCT02031653 - Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test
Completed NCT00605319 - An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia Phase 4
Recruiting NCT03503721 - Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate N/A
Not yet recruiting NCT05910983 - Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity N/A
Recruiting NCT03281798 - Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction N/A
Completed NCT05470751 - GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
Completed NCT04981080 - DU and BOO in Women With and Without Symptoms of VD
Completed NCT00410514 - A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Phase 2
Recruiting NCT06152666 - Day-case Endourology; Enablers, Barriers, Unexpected Outcomes
Not yet recruiting NCT04514718 - Low Energy HoLEP on IPSS N/A
Completed NCT01661621 - Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Phase 4